

**Chairperson: Eric Lowe, Myeloma UK**

- 10.00**      **Arrival, coffee and registration**
- 10.30**      **Welcome and Introduction**  
*Les Farrington,*  
Country Manager, Binding Site, UK & Ireland
- 10.45**      **Renal recovery from cast nephropathy  
using haemodialysis**  
*Dr Paul Cockwell,*  
Consultant Physician and Nephrologist,  
University Hospital Birmingham
- 11.30**      **MGUS risk stratification including  
Freelite**  
*Dr Judith Behrens,*  
Consultant Haematologist, St Helier Hospital,  
Carshalton
- 12.15**      **LUNCH**
- 13.15**      **Screening and monitoring Multiple  
Myeloma with Free Light Chains  
- Case studies**  
*Dr Majid Kazmi,*  
Consultant Haematologist, Guys and  
St Thomas's Hospital, London  
*Dr Martin Auger,*  
Consultant Haematologist, Norfolk and  
Norwich University Hospital, Norwich
- 14.30**      **Serum vs Urine for monoclonal  
gammopathies**  
*Dr Josie Hobbs,*  
Scientific Affairs Manager, Binding Site
- 15.15**      **What all this means - A patient  
perspective**  
*Eric Lowe,*  
Myeloma UK
- 15.45**      **Closing remarks**  
*Les Farrington*

**Chairperson: Eric Lowe, Myeloma UK**

- 10.00**      **Arrival, coffee and registration**
- 10.30**      **Welcome and Introduction**  
*Les Farrington,*  
Country Manager, Binding Site, UK & Ireland
- 10.45**      **Renal recovery from cast nephropathy  
using haemodialysis**  
*Dr Paul Cockwell,*  
Consultant Physician and Nephrologist,  
University Hospital Birmingham
- 11.30**      **MGUS risk stratification including  
Freelite**  
*Dr Judith Behrens,*  
Consultant Haematologist, St Helier Hospital,  
Carshalton
- 12.15**      **LUNCH**
- 13.15**      **Serum vs Urine for monoclonal  
gammopathies**  
*Dr David James,*  
Consultant Chemical Pathologist,  
Musgrove Park Hospital, Taunton
- 14.00**      **Screening and monitoring Multiple  
Myeloma with Free Light Chains  
- Case studies**  
*Dr Majid Kazmi,*  
Consultant Haematologist, Guys and  
St Thomas's Hospital, London  
*Dr Chris Poynton,*  
Consultant Haematologist,  
University Hospital Wales, Cardiff
- 15.15**      **What all this means - A patient  
perspective**  
*Eric Lowe,*  
Myeloma UK
- 15.45**      **Closing remarks**  
*Les Farrington*

# Birmingham 6th March 2008

**Chairperson: Eric Lowe, Myeloma UK**

- 10.00**      **Arrival, coffee and registration**
- 10.30**      **Welcome and Introduction**  
*Les Farrington,*  
Country Manager, Binding Site, UK & Ireland
- 10.45**      **Renal recovery from cast nephropathy  
using haemodialysis**  
*Dr Paul Cockwell,*  
Consultant Physician and Nephrologist,  
University Hospital Birmingham
- 11.30**      **MGUS risk stratification including  
Freelite**  
*Dr Graham Mead,*  
R&D Director, Binding Site & Hon Res Fellow,  
Division of Immunity and Infection,  
University of Birmingham
- 12.15**      **LUNCH**
- 13.15**      **Screening and monitoring Multiple  
Myeloma with Free Light Chains  
- Case studies**  
*Dr Guy Pratt,*  
Consultant Haematologist, Birmingham Heartlands  
Hospital, Birmingham  
*Dr Supratik Basu,*  
Consultant Haematologist, New Cross Hospital,  
Wolverhampton TBC
- 14.30**      **Serum vs Urine for monoclonal  
gammopathies**  
*Dr Tracy Lovatt,*  
Clinical Scientist, New Cross Hospital,  
Wolverhampton
- 15.15**      **What all this means - A patient  
perspective**  
*Eric Lowe,*  
Myeloma UK
- 15.45**      **Closing remarks**  
*Les Farrington*

**Chairperson: Eric Lowe, Myeloma UK**

- 10.00**      **Arrival, coffee and registration**
- 10.30**      **Welcome and Introduction**  
*Les Farrington,*  
Country Manager, Binding Site, UK & Ireland
- 10.45**      **Renal recovery from cast nephropathy  
using haemodialysis**  
*Prof. Arthur Bradwell,*  
Department of Immunology and Immunity,  
University of Birmingham
- 11.30**      **MGUS risk stratification including  
Freelite**  
*Dr Josie Hobbs,*  
Scientific Affairs Manager, Binding Site
- 12.15**      **LUNCH**
- 13.15**      **Screening and monitoring Multiple  
Myeloma with Free Light Chains  
- Case studies**  
*Dr Ade Olujohungbe,*  
Consultant Haematologist, University Hospital  
Aintree, Liverpool  
*Fiona Kilvington,*  
Scientific Support, Binding Site
- 14.30**      **Serum vs Urine for monoclonal  
gammopathies**  
*Dr Steven Holding,*  
Clinical Scientist, Hull Royal Infirmary, Hull
- 15.15**      **What all this means - A patient  
perspective**  
*Eric Lowe,*  
Myeloma UK
- 15.45**      **Closing remarks**  
*Les Farrington*